BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/23/2020 9:01:41 AM | Browse: 756 | Download: 1354
 |
Received |
|
2019-12-30 10:53 |
|
Peer-Review Started |
|
2019-12-30 10:55 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-01-28 21:53 |
|
Revised |
|
2020-03-21 14:56 |
|
Second Decision |
|
2020-03-25 06:19 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-03-26 13:24 |
|
Articles in Press |
|
2020-03-26 13:24 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-03-31 01:18 |
|
Typeset the Manuscript |
|
2020-04-16 12:28 |
|
Publish the Manuscript Online |
|
2020-04-23 09:01 |
| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Surgery |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Kin Pan Au and Kenneth Siu Ho Chok |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kenneth Siu Ho Chok, FACS, FRCS (Ed), MBBS, Associate Professor, Department of Surgery and State Key Laboratory for Liver Research, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong 999077, China. chok6275@hku.hk |
| Key Words |
Mammalian target of rapamycin inhibitor; Hepatocellular carcinoma; Recurrence; Liver transplant; Survival; Outcomes |
| Core Tip |
Mammalian target of rapamycin (mTOR) inhibitors have been shown to reduce the risk of tumour recurrence after liver transplantation for hepatocellular carcinoma (HCC). However, its role in established post-transplant HCC recurrence is uncertain. A retrospective study of 143 patients who developed HCC recurrence after liver transplantation was performed. Seventy-nine (55%) patients received mTOR inhibitor-based immunosuppressive regime while 64 (45%) of them did not. The median post-recurrence survival was 21.0 ± 4.1 mo in mTOR inhibitor group and 11.2 ± 2.5 mo in the control group. Multivariate cox regression analysis confirmed mTOR inhibitor was independently associated with improved post-recurrence survival (P = 0.04, OR 0.482, 95%CI: 0.241-0.966). |
| Publish Date |
2020-04-23 09:01 |
| Citation |
Au KP, Chok KSH. Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late? World J Gastrointest Surg 2020; 12(4): 149-158 |
| URL |
https://www.wjgnet.com/1948-9366/full/v12/i4/149.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v12.i4.149 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
